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Cytokines have recently emerged as important players in tumor promotion and progression. In this issue of
Cancer Cell, Putoczki and colleagues report the importance of interleukin 11 in a variety of gastrointestinal
malignances and lay down a framework for its potential inhibition in a variety of human cancers.Tumor microenvironment is increasingly
recognized as a pivotal player in tumori-
genesis. Cytokines are important media-
tors, connecting the inflammatory tumor
microenvironment and cancer cell gro-
wth. Cytokines are therefore potential
targets in cancer treatment, where their
blockade, parallel with conventional treat-
ments, allows the targeting of cancer cell
extrinsic tumor-promoting pathways.
The interleukin (IL)-6 family of cytokines
(including IL-6, IL-11, OSM, LIF, and
others) signal through their unique recep-
tor coupled with the common signaling
receptor chain gp130. gp130 signaling
activates at least three major pathways:
the JAK/STAT3 pathway, PI3K/mTOR
pathway, and Ras/ERK pathway. It is
assumed that the IL-6 family of cytokines
would elicit very similar (if not identical)
signaling outcomes, and the physiological
specificity of cytokine action is primarily
conferred by the tissue specificity of cyto-
kine and receptor expression, magnitude
and kinetic of their induction, and biolog-
ical availability of the ligand.
Among IL-6 family cytokines, IL-6 itself
elicited much attention, in part because
of its central role as a mediator of various
immune and homeostatic processes and
also because its level is highly upregu-
lated in many cancers correlating with
poor prognosis. STAT3 is an established
oncogene, whose activation within can-
cer cells and cells in the tumor microenvi-
ronment governs tumor growth and pro-
gression (Yu et al., 2009). IL-6 produced
by immune cells was shown to regulate
tumor multiplicity and growth in a mouse
model of colitis associated cancer (CAC)
(Becker et al., 2004; Grivennikov et al.,
2009) as well as spontaneous colorectal
cancer (CRC) (see Putoczki et al., 2013
in this issue of Cancer Cell), acting partic-ularly through STAT3 activation. While
clinical studies aiming to inhibit IL-6 in
human cancers are under way, it is clear
that IL-6 is not the sole STAT3-activating
cytokine and that STAT3 is not the only
one oncogenic pathway triggered by
cytokines in cancer.
In a quest to find additional cytokines
implicated in gastrointestinal cancers,
Putoczki et al. (2013) capitalized on pre-
vious observations that in a mouse model
of inflammation-driven gastric cancer
(GC) IL-11, but not IL-6, plays a pro-
tumorigenic role (Ernst et al., 2008) and
that the gp130/STAT3 pathway is essen-
tial for the pathogenesis of CAC (Bollrath
et al., 2009) and tested the role of IL-11
in a number of tumor models where IL-
11 mRNA and protein levels were signifi-
cantly upregulated in tumor tissues
(Figure 1A) (Putoczki et al., 2013). A
strength of the study is its inclusion of
animal models on different genetic back-
grounds, including C57Bl6 for APCMin
and IL-11 mutant (mutIL-11) studies,
BALB/c-nude for xenograft studies, and
mixed Sv129xC57Bl6 for other models.
Collectively, these models uniformly
allowed conclusions about the impor-
tance of IL-11 in tumorigenesis.
Using a CAC model, the authors
confirmed the importance of IL-6 in CAC
as previously published, but also found
a strikingly dominant role of IL-11 recep-
tor (IL-11R) in tumor emergence and
growth. Bone marrow transfer experi-
ments ascribed a pro-tumorigenic role to
IL-11R in radio-resistant cells, presum-
ably intestinal epithelium, in agreement
with the predominant role of gp130/
STAT3 expressed by epithelial cells in
CAC (Bollrath et al., 2009). An even more
significant effect of IL-11R inactivation
(compared with IL-6 inactivation) wasCancer Cell 24observed when CAC was induced in
gp130Y757F mice, which are unable to
terminate IL-6/IL-11 signaling and repre-
sent a model of gp130 pathway hyperac-
tivation. Because CAC represents only
2% of human CRC, an outstanding ques-
tion remained: is IL-11 signaling also
pivotal for CRC? Ablation of IL-11R
dramatically decreased in CRC tumorige-
nicity in gp130Y757F mice injected with the
mutagen azoxymethane (AOM) and in
APCMin mice, whereas inactivation of
IL-6 reduced CRC tumor burden in the
APCMin model but not in AOM-treated
gp130Y757F mice (Putoczki et al., 2013)
(Figure 1A). Next, the authors illustrated
the feasibility of the pharmacological
blockade of IL-11 signaling by using
mutIL-11, which binds to the IL-11R/
gp130 complex and blocks signal trans-
duction. They showed that mutIL-11
treatment reduced GC growth, reduced
tumor multiplicity and growth in CAC
model using WT and gp130Y757F mice,
and inhibited the growth of gastric and
colon cancer xenografts (Putoczki et al.,
2013).
What are the mechanisms by which
IL-11 drives gastrointestinal tumorigen-
esis? IL-11 has been long known to
induce STAT3 activation, and the current
data by Putoczki et al. (2013) indeed impli-
cate the STAT3 arm of signaling as the
most logical candidate. In all models, inhi-
bition of IL-11 signaling decreased levels
of p-STAT3 and pro-proliferative cyclins
and increased the level of the pro-
apoptotic protein BIM. Haploinsufficiency
in STAT3 leads to a similar protection from
tumorigenesis like IL-11R deficiency does
(Ernst et al., 2008; Putoczki et al., 2013).
In human CRC samples, the authors
observed a strong correlation between
IL-11 mRNA expression and the, August 12, 2013 ª2013 Elsevier Inc. 145
Figure 1. IL-11 Signaling Promotes Gastrointestinal Tumorigenesis
(A) The Putoczki et al. (2013) study demonstrates the dominant importance of IL-11-gp130 signaling in models of CAC, CRC, and GC.Whenmodels with the wild-
type gp130 are used, both IL-6 and IL-11 are required for tumor development. When models with the gp130Y757F mutant are used (indicated with a red star), the
tumorigenesis is solely dependent on IL-11. IL-11-gp130 signaling is required for enhanced cell proliferation and resistance to apoptosis.
(B) Although STAT3 pathway is important to mediate effects of IL-11 signaling, gp130 is also known to regulate the mTORC1 pathway and the Ras/ERK pathway.
The contribution of the mTORC1 pathway in GC and CAC has been previously demonstrated. IL-6 and IL-11 mostly activate an overlapping set of genes in can-
cer, with only a few of them being more specific for IL-6 or IL-11.
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Although such a correlation implies a
direct role of IL-11 in STAT3 activation, it
does not rule out the possibility that acti-
vated STAT3 directly drives the pro-
duction of IL-11 from epithelial cells,
thereby further increasing IL-11 levels in
p-STAT3high tumors. Is the STAT3
pathway an exclusive mediator of IL-11
action? To conclude so, it would be
important to see whether IL-11 can drive
tumorigenesis in mice devoid of STAT3
in their epithelial cells (Bollrath et al.,
2009). Another publication by the same
group suggests the importance of gp130
(and, presumably, IL-11)-mediated acti-
vation of mTORC1 pathway in gastric
cancer and CAC (Thiem et al., 2013). It is146 Cancer Cell 24, August 12, 2013 ª2013 Etempting to hypothesize that IL-11/IL-6-
gp130 signaling triggers both STAT3 and
mTORC1 activation, with each player
contributing to tumorigenesis (Figure 1B).
An important question is: why IL-11 has
a unique function apart from IL-6, which is
also present in tumors in seemingly large
amounts? Because IL-11 and IL-6 share
signaling pathways downstream of
gp130, it is unlikely that IL-11 and IL-6
induce large sets of non-overlapping
genes, and indeed only a very small num-
ber of genes preferentially regulated by
IL-6 or by IL-11 were found (Putoczki
et al., 2013) (Figure 1B). Although IL-11
protein levels were never quantified in
their study, mRNA analysis implied that
IL-11 expression levels were equal to orlsevier Inc.exceeded those of IL-6. In particular, in
the gp130Y757F model where constitu-
tively activated gp130 can induce more
IL-11 production by epithelial cells, IL-11
may completely override requirements
for IL-6. Likewise, the dynamics of IL-6R
and IL-11R expression as well as the
proximity of cytokine-producing cells to
tumor cells may be important (Putoczki
et al., 2013). IL-6 is primarily produced
by myeloid cells and T lymphocytes
(Becker et al., 2004; Grivennikov et al.,
2009), whereas IL-11 is made not only
by some immune cells and fibroblasts
but also epithelial cells, implicating
possible autocrine IL-11 signaling (Calon
et al., 2012; Putoczki et al., 2013). Dif-
ferential regulation of IL-6 and IL-11
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possibility. For example, IL-11 is known
to be regulated by STAT3, oncogenic in-
sults, and hypoxia that are constantly
present in the tumor microenvironment,
thereby allowing prolonged IL-11 produc-
tion, whereas IL-6 production by immune
cells may be more tightly and spatially
regulated. A recent study suggests that
CAC tumorigenicity depends on IL-6R
produced by epithelium in mice with
altered colonic microbiota (Hu et al.,
2013). Adding to the mix, there are other
STAT3-activating cytokines beyond IL-6
and IL-11, such as IL-22, that also can
regulate CAC and CRC development
(Huber et al., 2012).
The work by Putoczki et al. (2013)
expands our understanding of the role
that cytokine-induced signaling plays in
cancer and warrants further examination
of the modalities of IL-11 inhibition in
various solid tumors. Given that another
recent study identified the IL-11/STAT3
pathway as a critical regulator of humanCRC invasion and metastasis (Calon
et al., 2012), it is safe to conclude that
IL-11 constitutes an important compo-
nent of the tumormicroenvironment, influ-
encing every step of tumorigenesis and
representing an attractive target for pre-
ventive and therapeutic approaches.
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The master regulator of the classical cytoprotective ‘‘heat shock’’ response, heat shock factor 1 (HSF1), is
increasingly implicated in cancer pathogenesis, but the mechanisms remain poorly understood. A recent
study connects increased protein translation to activation of HSF1 in malignant cells and demonstrates
the therapeutic benefit of targeting this link.It is fast becoming clear that the stress-
activated transcription factor heat shock
factor 1 (HSF1) is not only the master
regulator of the classical heat shock
response and ‘‘guardian of the prote-
ome,’’ but is also a key player in aging
and oncogenesis (Anckar and Sistonen,
2011). The well-known activation of
HSF1 by elevated temperature or other
acute proteotoxic stressors leads to
increased transcription of genes involved
in protein quality control, thereby allow-
ing cells to survive the stress. The
emerging role of HSF1 in oncogenesisis best exemplified by Hsf1-knockout
mice having reduced susceptibility to
tumorigenesis driven by oncogenic
Ras or mutant p53 (Dai et al., 2007).
Accumulation and activation of nuclear
HSF1 is triggered by diverse cellular or
environmental stresses associated with
cancer. These include proteotoxic stress
or oncogenic stress (Dai et al., 2012a,
2012b).
Recent research unexpectedly re-
vealed an HSF1 gene expression program
in cancer cells distinct from, though over-
lapping with, the transcriptional profilein the classical heat shock response
(Mendillo et al., 2012). The HSF1 cancer
program comprises not only genes
encoding proteins mediating proteostasis
and survival, but also those facilitating
invasion and metastasis, cellular prolifer-
ation, protein synthesis, and glucose
metabolism. Importantly, the HSF1 can-
cer gene signature correlates strongly
with metastasis and survival in breast,
colon, and lung cancer patients.
Despite recent progress, the precise
molecular details of how HSF1 is acti-
vated in cancer are poorly understood., August 12, 2013 ª2013 Elsevier Inc. 147
